Drug Profile
Research programme: cancer therapeutics - 4SC
Alternative Names: 4SC-207Latest Information Update: 10 Oct 2013
Price :
$50
*
At a glance
- Originator 4SC
- Class Small molecules
- Mechanism of Action Aurora kinase inhibitors; Cell cycle inhibitors; Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 14 May 2013 Discontinued - Preclinical for Cancer in Germany (IV)
- 14 May 2013 Discontinued - Preclinical for Cancer in Germany (PO)
- 19 Mar 2013 Preclinical development is ongoing in Germany